NASDAQ: LYRALyra Therapeutics Inc Stock
$7.10-0.19 (-2.61%)
Updated Aug 14, 2025
LYRA Price
$7.10
Fair Value Price
-$3.07
Market Cap
$11.68M
52 Week Low
$3.81
52 Week High
$37.50
P/E
-0.24x
P/B
7.2x
P/S
15.69x
PEG
N/A
Dividend Yield
N/A
Revenue
$770.00k
Earnings
-$38.84M
Gross Margin
100%
Operating Margin
-5,041.17%
Profit Margin
-5,043.6%
Debt to Equity
31.41
Operating Cash Flow
-$43M
Beta
0.58
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LYRA Overview
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LYRA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LYRA
Ranked#241 of 481
Ranked#241 of 481
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $12.94 | A | |
| $12.09 | A | |
| $37.89 | A |
Be the first to know about important LYRA news, forecast changes, insider trades & much more!
LYRA News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LYRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LYRA ($7.10) is overvalued by 331.59% relative to our estimate of its Fair Value price of -$3.07 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
LYRA ($7.10) is not significantly undervalued (331.59%) relative to our estimate of its Fair Value price of -$3.07 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LYRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LYRA due diligence checks available for Premium users.
Valuation
LYRA fair value
Fair Value of LYRA stock based on Discounted Cash Flow (DCF)
Price
$7.10
Fair Value
-$3.07
Undervalued by
331.59%
LYRA ($7.10) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LYRA ($7.10) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LYRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LYRA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.24x
Industry
-116.18x
Market
36.29x
LYRA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
7.2x
Industry
4.42x
LYRA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LYRA's financial health
Profit margin
Revenue
$183.0k
Net Income
-$7.4M
Profit Margin
-4,063.9%
LYRA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
LYRA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$52.6M
Liabilities
$51.0M
Debt to equity
31.41
LYRA's short-term assets ($31.06M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LYRA's long-term liabilities ($39.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LYRA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
LYRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.6M
Investing
-$2.0k
Financing
$4.6M
LYRA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LYRA vs Biotech Stocks
Lyra Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.